Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880055 · ClinicalTrials.gov registry record
Shield Post-Approval Study Protocol
A clinical trial of Colo-rectal Cancer, sponsored by Guardant Health.
- Recruiting
- Registry status
- 3,375
- Enrollment target
- 20
- Study locations
NCT06880055 is a study of Colo-rectal Cancer that is actively recruiting participants, run by Guardant Health. The registered enrollment target is 3,375 participants, above the 2,500-participant average among 11 other Colo-rectal Cancer trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06880055, a study of Colo-rectal Cancer, is actively recruiting participants, sponsored by Guardant Health.
- RECRUITING
- Registry status
- 3,375 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Shield Blood Test for colo-rectal cancer Screening
Study Locations (20)
Illinois
- Digestive Disease Consultants - Bourbonnais
- Digestive Disease Consultants - Bourbonnais
- Christie Clinic - Champaign
- Christie Clinic - Champaign
- GI Solutions of Illinois - Chicago
- GI Solutions of Illinois - Chicago
- Digestive Health Services - Downers Grove
- Digestive Health Services - Downers Grove
- Gastroenterology and Internal Medicine Specialists (GAIMS) - Lake Barrington
- Gastroenterology and Internal Medicine Specialists (GAIMS) - Lake Barrington
California
- Alliance Research Institute, LLC - Canoga Park
- Paragon Rx Clinical, Inc. - Garden Grove
- Amicis Research Center - Granada Hills
- Desert Oasis Healthcare Medical Group - Palm Springs
Arizona
- Southeast Valley Gastroenterology Consultants - Chandler
- Southeast Valley Gastroenterology Consultants - Gilbert
Connecticut
- Digestive Disease Associates - Branford
- Digestive Disease Associates - Branford
Florida
- Gastroenterology Consultants of Boca Raton, LLC - Boca Raton
- Physicians Group of South Florida - North Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,375 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2030-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06880055
The ClinicalTrials.gov registry entry for NCT06880055 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,500-participant average among 11 other Colo-rectal Cancer trials with a reported enrollment target (35% higher). The listed sponsor is Guardant Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colo-rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Shield Blood Test for colo-rectal cancer Screening is the first listed.
NCT06880055 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Illinois, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06880055 about?
NCT06880055 is a clinical study titled "Shield Post-Approval Study Protocol". The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi...
What is the current status of trial NCT06880055?
This trial is currently recruiting. The enrollment target is 3,375 participants. The study started on 2025-07-14. Estimated completion is 2030-12-01.
What conditions does trial NCT06880055 study?
This clinical trial studies the following conditions: Colo-rectal Cancer.
What interventions are being tested in trial NCT06880055?
The interventions under investigation include: Shield Blood Test for colo-rectal cancer Screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06880055?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06880055 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colo-rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
RECRUITING · NA
-
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
RECRUITING · Phase 2
-
Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.